Halozyme Therapeutics (HALO) reported quarterly earnings results on Monday, May-9-2016. The company said it had a profit of $-0.16 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.06. Analysts had a consensus of $-0.22. The company posted revenue of $42.50 million in the period, compared to analysts expectations of $28.58 million. The company’s revenue was up 127.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.12 EPS.
Halozyme Therapeutics closed down -0.13 points or -1.35% at $9.5 with 13,37,180 shares getting traded on Friday. Post opening the session at $9.5, the shares hit an intraday low of $9.25 and an intraday high of $9.9 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
In a different news, on Aug 26, 2015, Laurie Stelzer (CFO) purchased 10,000 shares at $17.24 per share price. According to the SEC, on Jun 22, 2015, Kenneth J Kelley (director) sold 20,000 shares at $21.00 per share price.
Halozyme Therapeutics Inc. is a biotechnology company which is focused on developing and commercializing oncology therapies that target the tumor microenvironment. The Companys development pipeline consists primarily of clinical-stage product candidates in oncology and diabetes. The product candidates in its pipeline are based on rHuPH20 a human recombinant hyaluronidase enzyme. rHuPH20 temporarily breaks down hyaluronic acid (HA). Its lead oncology program is PEGPH20 (PEGylated recombinant human hyaluronidase) a new molecular entity under development for the systemic treatment of tumors that accumulate HA. The Company is in collaboration with pharmaceutical companies including Roche Pfizer Janssen and Baxter for its drug delivery platform ENHANZE which enables biologics and small molecule compounds that are administered intravenously to be delivered subcutaneously.